• Veraxa Biotech advanced bispecific antibody-drug conjugate program VXA-222 into its next internal development phase following a key technical milestone.
• OmniAb’s discovery work under the May 2025 alliance concluded, delivering human antibody leads to support VXA-222.
• VXA-222 uses an “AND-gate” bispecific design to target two solid-tumor antigens with one molecule.
• Veraxa will apply its proprietary linker and conjugation technology, then run in vitro and in vivo validation to establish a lead candidate.
• Veraxa holds exclusive development and commercialization rights; OmniAb will receive a share of specified product revenue.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veraxa Biotech AG published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001829126-26-007881), on July 27, 2026, and is solely responsible for the information contained therein.